Research programme: sigma receptor modulators - Anavex Life SciencesAlternative Names: ANAVEX 1005; ANAVEX 1007; ANAVEX 1066; ANAVEX 1067; ANAVEX 1079; ANAVEX 1519; ANAVEX 27-1041; ANAVEX 28-1078; ANAVEX 30-1022; ANAVEX 35-3016; ANAVEX 40-1042; ANAVEX 7-1037; ANAVEX 8-142; Cancer therapeutics - Anavex Life Sciences; Sigmaceptor-C™ programme
Latest Information Update: 18 Nov 2016
At a glance
- Originator Anavex Life Sciences
- Class Small molecules
- Mechanism of Action Chloride channel modulators; Muscarinic M3 receptor antagonists; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sigma-2 receptor agonists; Sigma-2 receptor antagonists; Sodium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute pain; Malignant melanoma; Neuropathic pain; Ovarian cancer; Pain; Pancreatic cancer; Prostate cancer; Solid tumours